Ask about this productRelated genes to: CD104 antibody
- Gene:
- ITGB4 NIH gene
- Name:
- integrin subunit beta 4
- Previous symbol:
- -
- Synonyms:
- CD104
- Chromosome:
- 17q25.1
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-06
- Date modifiied:
- 2015-12-15
Related products to: CD104 antibody
Related articles to: CD104 antibody
- - Source: PubMed
Publication date: 2026/04/30
Liu SihanQiao HongjiangLiu ZhiFang HuiQiao PeiZuo Yagang - Rejuvenating aging human skin is a major therapeutic goal, but objective, quantitative measures of intrinsic aging are limited. We performed a cross-sectional histological study of UV-protected buttock and abdominal skin in adults spanning multiple decades of life to identify features that reliably track age. Epidermal thickness measured between rete ridges was unchanged, but rete ridge size declined linearly with age: ridges became shorter and thinner in both sites, though rete ridge number decreased only in the abdomen. Consistent with these structural changes, proliferative cells (Ki67+) per ridge and expression of integrin β4 (ITGB4), a putative stem-cell marker, were reduced in aged skin. We combined these biomarkers into a predictive model that estimated skin age more accurately than any single marker. To test whether the model detects longitudinal change, we analyzed aged abdominal skin before and after xenografting onto young or aged mice, a procedure previously reported to rejuvenate human skin in young but not aged recipient mice. Both individual biomarkers and the imaging model indicated rejuvenation regardless of host age; however, notably, engraftment efficiency was lower in aged hosts, with surviving grafts showing younger histological phenotypes. These results provide quantitative criteria for assessing intrinsic skin aging and suggest that the process of engraftment itself is sufficient to induce rejuvenation-like changes. - Source: PubMed
Publication date: 2026/05/04
Lefebvre Austin E Y TZheng YingYang RuifengLan FionaNace ArbenKatz EmilieLibert SergiyKenyon CynthiaPodshivalova KatieCotsarelis George - Breast carcinoma is a major cause of cancer-related mortality among women worldwide. Identifying novel molecular targets remains essential, particularly for aggressive triple-negative breast cancer (TNBC). Leucine-rich alpha-2-glycoprotein 1 (LRG1) has been linked to tumor progression and angiogenesis, but its molecular mechanisms in breast cancer are poorly defined. We evaluated the effects of recombinant human LRG1 (rhLRG1) on cell viability and migration in MDA-MB-231 TNBC cells and performed transcriptomic profiling followed by functional enrichment analyses using GenArise, Cytoscape, and R-based tools. RhLRG1 treatment significantly increased cell viability and migration. Transcriptomic analysis revealed activation of key oncogenic cascades, including the PI3K/AKT, MAPK, and RAS signaling pathways. Hub-gene analysis identified upregulated genes involved in proliferation (, , ), angiogenesis (, ), and apoptosis (, ), whereas downregulated genes were associated with apoptotic resistance (, ) and adhesion (, ). Functional enrichment highlighted LRG1's role in the bioinformatic analysis of differentially expressed genes that were obtained from microarray assays. LRG1 remodels the tumor microenvironment by promoting proliferation, angiogenesis, and apoptotic sensitivity while repressing resistance-related genes. These findings position LRG1 as a potential diagnostic biomarker and therapeutic target for advanced breast carcinoma. - Source: PubMed
Publication date: 2026/04/18
Osorio-Antonio FedericoDiaz-González Daniela MichelCampos-Viguri Gabriela ElizabethSánchez-López José ManuelCortez-Sánchez José LuisCastelán FranciscoChávez-Rios Jesús RamsesMaycotte-González PaolaCortés-Hernández PaulinaPeralta-Zaragoza OscarBautista-Rodríguez Elizabeth - Peri-implant soft tissue integration and compatibility is critical for the long-term success of implant-supported restorations. Ceramics used with Ti-base abutments differ in their physicochemical properties and biological behavior. However, these differences remain incompletely understood. - Source: PubMed
Publication date: 2026/04/24
Altıok DorukCoşar BegümSancar EcemKılıç PelinErkut Selim - Integrin beta 4 (ITGB4) has been implicated in breast cancer progression, yet its clinical utility as a biomarker remains unclear due to inconsistent findings across studies. This discrepancy may stem from the failure to distinguish between RNA and protein levels. - Source: PubMed
Zhu Zhi-MinHu LeiMa Yan-WenZhu Qiong-Ni